SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company's operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. It aggregates components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:


•	Japan


•	EMEA


•	North America Plasma


•	All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments, accelerated depreciation and certain legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

During the first quarter of fiscal 2019, management reorganized its operating segments such that certain immaterial components of EMEA are now reported as components of All Other. Accordingly, the prior year numbers have been updated to reflect this reclassification as well as other changes within the cost reporting structure that occurred in the first quarter of fiscal 2019. These changes did not have an impact on its ability to aggregate Americas Blood Center and Hospital with Asia - Pacific.

Selected information by business segment is presented below:



	Three Months Ended						Six Months Ended
(In thousands)	September 29, 2018			September 30, 2017			September 29, 2018			September 30, 2017
Net revenues
Japan	$	17,343		$	17,164		$	33,947		$	32,396
EMEA	40,051			41,428			81,339			81,867
North America Plasma	99,655			85,051			191,229			162,587
All Other	85,482			82,551			165,294			163,294
Net revenues before foreign exchange impact	242,531			226,194			471,809			440,144
Effect of exchange rates	(950		)	(817		)	(881		)	(3,816		)
Net revenues	$	241,581		$	225,377		$	470,928		$	436,328



	Three Months Ended						Six Months Ended
(In thousands)	September 29, 2018			September 30, 2017			September 29, 2018			September 30, 2017
Segment operating income
Japan	$	9,366		$	8,656		$	17,633		$	16,123
EMEA	11,459			10,026			23,499			20,524
North America Plasma	41,468			34,692			80,064			61,892
All Other	36,229			32,529			69,270			63,199
Segment operating income	98,522			85,903			190,466			161,738
Corporate operating expenses	(62,244		)	(50,456		)	(116,517		)	(98,505		)
Effect of exchange rates	2,594			1,102			5,649			(1,099		)
Restructuring and turnaround costs	(2,118		)	(5,787		)	(5,467		)	(8,270		)
Deal amortization	(6,236		)	(6,504		)	(12,536		)	(12,995		)
Asset impairments	—			—			(21,170		)	—
Accelerated depreciation	(4,442		)	—			(8,381		)	—
Legal charges	—			—			(675		)	—
Operating income	$	26,076		$	24,258		$	31,369		$	40,869

The Company's products are organized into three categories for purposes of evaluating their growth potential: Plasma, Blood Center and Hospital. Management reviews revenue trends based on these business units.

Net revenues by business unit are as follows:



	Three Months Ended				Six Months Ended
(In thousands)	September 29, 2018		September 30, 2017		September 29, 2018		September 30, 2017
Plasma	$	124,352	$	109,771	$	241,255	$	211,278
Blood Center	68,243		71,710		132,726		137,275
Hospital	48,986		43,896		96,947		87,775
Net revenues	$	241,581	$	225,377	$	470,928	$	436,328

Net revenues generated in the Company's principle operating regions on a reported basis are as follows:



	Three Months Ended				Six Months Ended
(In thousands)	September 29, 2018		September 30, 2017		September 29, 2018		September 30, 2017
United States	$	152,926	$	138,779	$	295,066	$	269,831
Japan	17,172		16,732		34,561		31,648
Europe	39,096		39,133		78,098		76,355
Asia	30,575		28,831		59,970		54,771
Other	1,812		1,902		3,233		3,723
Net revenues	$	241,581	$	225,377	$	470,928	$	436,328